Clinical Trials Directory

Trials / Completed

CompletedNCT01970137

A 24-week Open-label Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD)

Status
Completed
Phase
Phase 3
Study type
Interventional
Enrollment
Sponsor
Kissei Pharmaceutical Co., Ltd. · Industry
Sex
All
Age
20 Years
Healthy volunteers

Summary

The purpose of this study is to evaluate the safety, efficacy, and pharmacokinetics of KPS-0373 in SCD patients (Experience of clinical trials of KPS-0373)

Conditions

Interventions

TypeNameDescription
DRUGKPS-0373, High dose
DRUGKPS-0373, Low dose

Timeline

Primary completion
2014-10-01
First posted
2013-10-25
Last updated
2016-04-18

Locations

1 site across 1 country: Japan

Source: ClinicalTrials.gov record NCT01970137. Inclusion in this directory is not an endorsement.